ALK and neoplasm: Intratumoral and intertumoral heterogeneity including temporal heterogeneity from treatment selection pressure is expected with ALK, with acquired drug-resistant progressing sites of disease expected to harbor a unique genomic profile to the primary tumor and controlled sites of disease.